Contraline Closes $10.7 Million Series A Financing to Become a Clinical Stage Company
22 Oct, 2021
Neurophth Closes RMB 400 Million Series B Financing
– Neurophth Biotechnology Ltd. announced the closing of a RMB 400 million ($61.9 million USD) Series-B financing with a premier syndicate of investors, co-led by Guofang Capital and InnoVision Capital.
– Neurophth is a fully-integrated genetic medicines company developing AAV-delivered gene therapies for the treatment of ocular diseases.
– The company has an extensive portfolio of potentially curative gene therapies for the treatment of ocular genetic diseases.
